OncoCyte Corp (OCX)

5.78
AMEX : Health Care
Prev Close 5.80
Day Low/High 5.78 / 5.90
52 Wk Low/High 3.10 / 7.95
Avg Volume 17.50K
Exchange AMEX
Shares Outstanding 29.36M
Market Cap 170.30M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

OncoCyte Receives $2 Million In Proceeds From Early Exercise Of Warrants

OncoCyte Receives $2 Million In Proceeds From Early Exercise Of Warrants

Completes Sample Collection and Processing for the 300-Patient Study of its Lung Cancer Diagnostic Test

OncoCyte Becomes Oversold (OCX)

OncoCyte Becomes Oversold (OCX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Don M. Bailey Appointed To OncoCyte Corporation's Board Of Directors

Don M. Bailey Appointed To OncoCyte Corporation's Board Of Directors

Experienced Senior Executive with Track Record of Consistently and Rapidly Building Shareholder Value at Several Companies Makes Equity Investment in OncoCyte

OncoCyte Corporation Announces The Closing Of Two Private Placement Transactions Generating Gross Proceeds Of $10.55 Million

OncoCyte Corporation Announces The Closing Of Two Private Placement Transactions Generating Gross Proceeds Of $10.55 Million

Net Proceeds to be Used to Continue R&D of Non-Invasive Cancer Diagnostics Tests and CLIA Compliant Laboratory Build-Out

OncoCyte Reports Second Quarter 2016 Financial Results

OncoCyte Reports Second Quarter 2016 Financial Results

Conference Call to Discuss the Results at 5:00 p.m. ET

OncoCyte Commences Analytical Verification Study For Lung Cancer Diagnostic Test

OncoCyte Commences Analytical Verification Study For Lung Cancer Diagnostic Test

Expects to Complete the Studies Later this Year and Continues to Project Commercial Launch in the First Half of 2017

BioTime, Inc. Reports Second Quarter Results And Recent Corporate Accomplishments

BioTime, Inc. Reports Second Quarter Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today reported financial results for the second quarter ended June 30, 2016 and provided a...

WireCo Announces Investment From Onex

WireCo Announces Investment From Onex